AbbVie Inc. Increase (Decrease) in Accounts Receivable
AbbVie Inc. (ABBV) reported Increase (Decrease) in Accounts Receivable of $1.28 billion for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-03.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsReceivable · last filed 2026-08-03
- AbbVie Inc. increase (decrease) in accounts receivable for the quarter ending 2026-06-30 was $1.37B, a 7952.94% increase year-over-year.
- AbbVie Inc. increase (decrease) in accounts receivable for the quarter ending 2026-03-31 was -$87.00M, a 105.88% decline year-over-year.
- AbbVie Inc. increase (decrease) in accounts receivable for the quarter ending 2025-12-31 was -$162.00M.
- AbbVie Inc. increase (decrease) in accounts receivable for the quarter ending 2025-09-30 was $156.00M.
- AbbVie Inc. increase (decrease) in accounts receivable for fiscal 2025 was $1.49B.
- AbbVie Inc. increase (decrease) in accounts receivable for fiscal 2024 was -$207.00M.
- AbbVie Inc. increase (decrease) in accounts receivable for fiscal 2023 was -$66.00M, a 104.54% decline from fiscal 2022.
- AbbVie Inc. increase (decrease) in accounts receivable for fiscal 2022 was $1.46B, a 10.14% increase from fiscal 2021.
| Period end | Increase (Decrease) in Accounts Receivable 3 month | Increase (Decrease) in Accounts Receivable 6 month | Increase (Decrease) in Accounts Receivable 9 month | Increase (Decrease) in Accounts Receivable 12 month |
|---|---|---|---|---|
| 2026-06-30 | $1.37B derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-03 | $1.28B 10-Q · filed 2026-08-03 | $1.12B derived: sum of 3 quarters · filed 2026-08-03 | $1.28B derived: sum of 4 quarters · filed 2026-08-03 |
| 2026-03-31 | -$87.00M 10-Q · filed 2026-05-08 | -$249.00M derived: sum of 2 quarters · filed 2026-05-08 | -$93.00M derived: sum of 3 quarters · filed 2026-05-08 | -$76.00M derived: sum of 4 quarters · filed 2026-08-03 |
| 2025-12-31 | -$162.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-20 | -$6.00M derived: sum of 2 quarters · filed 2026-02-20 | $11.00M derived: sum of 3 quarters · filed 2026-08-03 | $1.49B 10-K · filed 2026-02-20 |
| 2025-09-30 | $156.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $173.00M derived: sum of 2 quarters · filed 2026-08-03 | $1.65B 10-Q · filed 2025-11-04 | $1.26B derived: sum of 4 quarters · filed 2026-08-03 |
| 2025-06-30 | $17.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-03 | $1.50B 10-Q · filed 2026-08-03 | $1.11B derived: sum of 3 quarters · filed 2026-08-03 | $765.00M derived: sum of 4 quarters · filed 2026-08-03 |
| 2025-03-31 | $1.48B 10-Q · filed 2026-05-08 | $1.09B derived: sum of 2 quarters · filed 2026-05-08 | $748.00M derived: sum of 3 quarters · filed 2026-05-08 | $570.00M derived: sum of 4 quarters · filed 2026-05-08 |
| 2024-12-31 | -$387.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-20 | -$731.00M derived: sum of 2 quarters · filed 2026-02-20 | -$909.00M derived: sum of 3 quarters · filed 2026-02-20 | -$207.00M 10-K · filed 2026-02-20 |
| 2024-09-30 | -$344.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | -$522.00M derived: sum of 2 quarters · filed 2025-11-04 | $180.00M 10-Q · filed 2025-11-04 | -$159.00M derived: sum of 4 quarters · filed 2026-02-20 |
| 2024-06-30 | -$178.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-04 | $524.00M 10-Q · filed 2025-08-04 | $185.00M derived: sum of 3 quarters · filed 2026-02-20 | $183.00M derived: sum of 4 quarters · filed 2026-02-20 |
| 2024-03-31 | $702.00M 10-Q · filed 2025-05-09 | $363.00M derived: sum of 2 quarters · filed 2026-02-20 | $361.00M derived: sum of 3 quarters · filed 2026-02-20 | $441.00M derived: sum of 4 quarters · filed 2026-02-20 |
| 2023-12-31 | -$339.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-20 | -$341.00M derived: sum of 2 quarters · filed 2026-02-20 | -$261.00M derived: sum of 3 quarters · filed 2026-02-20 | -$66.00M 10-K · filed 2026-02-20 |
| 2023-09-30 | -$2.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-04 | $78.00M derived: sum of 2 quarters · filed 2024-11-04 | $273.00M 10-Q · filed 2024-11-04 | $689.00M derived: sum of 4 quarters · filed 2025-02-14 |
| 2023-06-30 | $80.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-07 | $275.00M 10-Q · filed 2024-08-07 | $691.00M derived: sum of 3 quarters · filed 2025-02-14 | $334.00M derived: sum of 4 quarters · filed 2025-02-14 |
| 2023-03-31 | $195.00M 10-Q · filed 2024-05-03 | $611.00M derived: sum of 2 quarters · filed 2025-02-14 | $254.00M derived: sum of 3 quarters · filed 2025-02-14 | $865.00M derived: sum of 4 quarters · filed 2025-02-14 |
| 2022-12-31 | $416.00M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-14 | $59.00M derived: sum of 2 quarters · filed 2025-02-14 | $670.00M derived: sum of 3 quarters · filed 2025-02-14 | $1.46B 10-K · filed 2025-02-14 |
| 2022-09-30 | -$357.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-06 | $254.00M derived: sum of 2 quarters · filed 2023-11-06 | $1.04B 10-Q · filed 2023-11-06 | $1.79B derived: sum of 4 quarters · filed 2024-02-20 |
| 2022-06-30 | $611.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-07 | $1.40B 10-Q · filed 2023-08-07 | $2.15B derived: sum of 3 quarters · filed 2024-02-20 | $1.55B derived: sum of 4 quarters · filed 2024-02-20 |
| 2022-03-31 | $785.00M 10-Q · filed 2023-05-05 | $1.53B derived: sum of 2 quarters · filed 2024-02-20 | $944.00M derived: sum of 3 quarters · filed 2024-02-20 | $1.24B derived: sum of 4 quarters · filed 2024-02-20 |
| 2021-12-31 | $749.00M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-20 | $159.00M derived: sum of 2 quarters · filed 2024-02-20 | $455.00M derived: sum of 3 quarters · filed 2024-02-20 | $1.32B 10-K · filed 2024-02-20 |
| 2021-09-30 | -$590.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-04 | -$294.00M derived: sum of 2 quarters · filed 2022-11-04 | $572.00M 10-Q · filed 2022-11-04 | $927.00M derived: sum of 4 quarters · filed 2023-02-17 |
| 2021-06-30 | $296.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | $1.16B 10-Q · filed 2022-08-04 | $1.52B derived: sum of 3 quarters · filed 2023-02-17 | $1.55B derived: sum of 4 quarters · filed 2023-02-17 |
| 2021-03-31 | $866.00M 10-Q · filed 2022-05-06 | $1.22B derived: sum of 2 quarters · filed 2023-02-17 | $1.25B derived: sum of 3 quarters · filed 2023-02-17 | $770.00M derived: sum of 4 quarters · filed 2023-02-17 |
| 2020-12-31 | $355.00M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-17 | $386.00M derived: sum of 2 quarters · filed 2023-02-17 | -$96.00M derived: sum of 3 quarters · filed 2023-02-17 | $929.00M 10-K · filed 2023-02-17 |
| 2020-09-30 | $31.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-02 | -$451.00M derived: sum of 2 quarters · filed 2021-11-02 | $574.00M 10-Q · filed 2021-11-02 | $441.00M derived: sum of 4 quarters · filed 2022-02-18 |
| 2020-06-30 | -$482.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-02 | $543.00M 10-Q · filed 2021-08-02 | $410.00M derived: sum of 3 quarters · filed 2022-02-18 | $521.00M derived: sum of 4 quarters · filed 2022-02-18 |
| 2020-03-31 | $1.02B 10-Q · filed 2021-05-07 | $892.00M derived: sum of 2 quarters · filed 2022-02-18 | $1.00B derived: sum of 3 quarters · filed 2022-02-18 | $783.00M derived: sum of 4 quarters · filed 2022-02-18 |
| 2019-12-31 | -$133.00M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-18 | -$22.00M derived: sum of 2 quarters · filed 2022-02-18 | -$242.00M derived: sum of 3 quarters · filed 2022-02-18 | $74.00M 10-K · filed 2022-02-18 |
| 2019-09-30 | $111.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-04 | -$109.00M derived: sum of 2 quarters · filed 2020-11-04 | $207.00M 10-Q · filed 2020-11-04 | -$8.00M derived: sum of 4 quarters · filed 2021-02-19 |
| 2019-06-30 | -$220.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-04 | $96.00M 10-Q · filed 2020-08-04 | -$119.00M derived: sum of 3 quarters · filed 2021-02-19 | -$118.00M derived: sum of 4 quarters · filed 2021-02-19 |
| 2019-03-31 | $316.00M 10-Q · filed 2020-05-08 | $101.00M derived: sum of 2 quarters · filed 2021-02-19 | $102.00M derived: sum of 3 quarters · filed 2021-02-19 | $226.00M derived: sum of 4 quarters · filed 2021-02-19 |
| 2018-12-31 | -$215.00M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-19 | -$214.00M derived: sum of 2 quarters · filed 2021-02-19 | -$90.00M derived: sum of 3 quarters · filed 2021-02-19 | $591.00M 10-K · filed 2021-02-19 |
| 2018-09-30 | $1.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-06 | $125.00M derived: sum of 2 quarters · filed 2019-11-06 | $806.00M 10-Q · filed 2019-11-06 | $1.03B derived: sum of 4 quarters · filed 2020-02-21 |
| 2018-06-30 | $124.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-05 | $805.00M 10-Q · filed 2019-08-05 | $1.03B derived: sum of 3 quarters · filed 2020-02-21 | $1.03B derived: sum of 4 quarters · filed 2020-02-21 |
| 2018-03-31 | $681.00M 10-Q · filed 2019-05-03 | $909.00M derived: sum of 2 quarters · filed 2020-02-21 | $905.00M derived: sum of 3 quarters · filed 2020-02-21 | $1.04B derived: sum of 4 quarters · filed 2020-02-21 |
| 2017-12-31 | $228.00M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-21 | $224.00M derived: sum of 2 quarters · filed 2020-02-21 | $357.00M derived: sum of 3 quarters · filed 2020-02-21 | $391.00M 10-K · filed 2020-02-21 |
| 2017-09-30 | -$4.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-07 | $129.00M derived: sum of 2 quarters · filed 2018-11-07 | $163.00M 10-Q · filed 2018-11-07 | $105.00M derived: sum of 4 quarters · filed 2019-02-27 |
| 2017-06-30 | $133.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-07 | $167.00M 10-Q · filed 2018-08-07 | $109.00M derived: sum of 3 quarters · filed 2019-02-27 | $44.00M derived: sum of 4 quarters · filed 2019-02-27 |
| 2017-03-31 | $34.00M 10-Q · filed 2018-05-04 | -$24.00M derived: sum of 2 quarters · filed 2019-02-27 | -$89.00M derived: sum of 3 quarters · filed 2019-02-27 | $186.00M derived: sum of 4 quarters · filed 2019-02-27 |
| 2016-12-31 | -$58.00M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-27 | -$123.00M derived: sum of 2 quarters · filed 2019-02-27 | $152.00M derived: sum of 3 quarters · filed 2019-02-27 | $71.00M 10-K · filed 2019-02-27 |
| 2016-09-30 | -$65.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-07 | $210.00M derived: sum of 2 quarters · filed 2017-11-07 | $129.00M 10-Q · filed 2017-11-07 | $363.00M derived: sum of 4 quarters · filed 2018-02-16 |
| 2016-06-30 | $275.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-07 | $194.00M 10-Q · filed 2017-08-07 | $428.00M derived: sum of 3 quarters · filed 2018-02-16 | $682.00M derived: sum of 4 quarters · filed 2018-02-16 |
| 2016-03-31 | -$81.00M 10-Q · filed 2017-05-05 | $153.00M derived: sum of 2 quarters · filed 2018-02-16 | $407.00M derived: sum of 3 quarters · filed 2018-02-16 | $451.00M derived: sum of 4 quarters · filed 2018-02-16 |
| 2015-12-31 | $234.00M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-16 | $488.00M derived: sum of 2 quarters · filed 2018-02-16 | $532.00M derived: sum of 3 quarters · filed 2018-02-16 | $1.08B 10-K · filed 2018-02-16 |
| 2015-09-30 | $254.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-07 | $298.00M derived: sum of 2 quarters · filed 2016-11-07 | $842.00M 10-Q · filed 2016-11-07 | |
| 2015-06-30 | $44.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-05 | $588.00M 10-Q · filed 2016-08-05 | ||
| 2015-03-31 | $544.00M 10-Q · filed 2016-05-06 | |||
| 2014-12-31 | $172.00M 10-K · filed 2017-02-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Merck & Co., Inc. (MRK) | United States | $365.215B | 99.96 |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |